A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

NCT01631942 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped See detailed description

Conditions

Congenital Bleeding Disorder
Haemophilia A
Healthy

Interventions

DRUG: NNC172-2021

Sponsor

Novo Nordisk A/S